Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety data from the Chinese subpopulation are reported. Methods: IMb...

Full description

Bibliographic Details
Main Authors: Shukui Qin, Zhenggang Ren, Yin-Hsun Feng, Thomas Yau, Baocheng Wang, Haitao Zhao, Yuxian Bai, Shanzhi Gu, Lindong Li, Sairy Hernandez, Derek-Zhen Xu, Sohail Mulla, Yifan Wang, Hui Shao, Ann Lii Cheng
Format: Article
Language:English
Published: Karger Publishers 2021-04-01
Series:Liver Cancer
Subjects:
checkpoint inhibitor
immunotherapy
liver cancer
systemic treatment
chinese patients
overall survival
programmed death-ligand 1 inhibitor
Online Access:https://www.karger.com/Article/FullText/513486

Internet

https://www.karger.com/Article/FullText/513486

Similar Items